How to Image Hypertrophic Cardiomyopathy.

A 48-year-old man, with only a history of mild systemic hypertension, was initially evaluated after presenting with symptoms of exertional dyspnea occurring predominantly with inclines. At that time, an abnormal 12-lead ECG was obtained demonstrating left ventricular hypertrophy by conventional voltage criteria, prompting additional testing with a 2-dimensional echocardiogram that showed normal systolic function (ejection fraction=65%), with 14-mm ventricular septal thickness and 12 mm in the posterolateral wall, and mild systolic anterior motion (SAM) of the mitral valve (bend of anterior leaflet into outflow tract without septal contact). A stress nuclear stress test showed no myocardial ischemia at rest or at peak exercise with a normal blood pressure response and no arrhythmias or ST-T changes during exercise or in recovery. The patient was prescribed a β-blocker for treatment of systemic hypertension. During the next 2 years, the patient developed more limiting exertional symptoms with routine activities. β-Blocker dosage was increased, and a repeat echocardiogram demonstrated similar findings to the initial study, borderline left ventricular (LV) wall thickness despite well-controlled blood pressure. The abnormal ECG, and mild SAM at rest, raised consideration for a diagnosis of hypertrophic cardiomyopathy (HCM) and management for limiting heart failure symptoms. HCM is often suspected in a patient based on the presence of cardiovascular symptoms, detection of abnormal ECG, systolic ejection murmur on routine examination, or as part of pedigree screening.1,2 Abnormalities on ECG are present in >90% of patients with HCM, although no specific ECG pattern is pathognomonic.1 Clinical diagnosis of HCM can reliably be made in the majority of patients with 2-dimensional transthoracic echocardiography by imaging increased LV wall thickness (≥15 mm) with a nondilated cavity in the absence of any disease known to cause LV hypertrophy of that magnitude (ie, systemic hypertension or aortic stenosis).1–5 In …

[1]  M. Link,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. , 2017, Journal of the American College of Cardiology.

[2]  B. Maron,et al.  A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. , 2016, The American journal of cardiology.

[3]  R. Chan,et al.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. , 2016, JACC. Cardiovascular imaging.

[4]  L. Axel,et al.  The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context. , 2016, Journal of the American College of Cardiology.

[5]  M. Link,et al.  Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[6]  W. Manning,et al.  Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. , 2015, The American journal of cardiology.

[7]  N. Geller,et al.  Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. , 2015, American heart journal.

[8]  B. Maron,et al.  Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy , 2015, Circulation.

[9]  N. Smedira,et al.  Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. , 2015, Circulation. Cardiovascular imaging.

[10]  D. Kaye,et al.  Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. , 2015, European heart journal cardiovascular Imaging.

[11]  Martin Borggrefe,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[12]  D. Bluemke,et al.  Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy , 2014, Circulation. Cardiovascular imaging.

[13]  K. Siminovitch,et al.  Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. , 2014, European heart journal.

[14]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[15]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[16]  Barry J Maron,et al.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.

[17]  B. Maron,et al.  Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. , 2014, The American journal of cardiology.

[18]  D. Pennell,et al.  Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy , 2014, Heart.

[19]  S. Colan,et al.  Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers Without Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular genetics.

[20]  B. Maron,et al.  Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. , 2013, The American journal of cardiology.

[21]  Harry Rakowski,et al.  Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. , 2013, JACC. Cardiovascular imaging.

[22]  R. Kwong,et al.  T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular imaging.

[23]  S. K. White,et al.  Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping , 2013, Circulation. Cardiovascular imaging.

[24]  Andrew S Flett,et al.  Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease , 2012, Heart.

[25]  Barry J Maron,et al.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. , 2012, Journal of the American College of Cardiology.

[26]  M. Maron,et al.  Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy , 2012, Journal of Cardiovascular Magnetic Resonance.

[27]  W. Manning,et al.  Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy , 2011, Circulation. Cardiovascular imaging.

[28]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[29]  Vasken Dilsizian,et al.  American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomograph , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[30]  Vivek Muthurangu,et al.  Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.

[31]  W. Manning,et al.  Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy , 2010, Circulation.

[32]  B. Maron,et al.  Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[33]  G. Boriani,et al.  Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[34]  M. Sherrid,et al.  Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. , 2008, The Annals of thoracic surgery.

[35]  Jeroen J. Bax,et al.  Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. , 2008, JACC. Cardiovascular imaging.

[36]  Luigi Rega,et al.  Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[37]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[38]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2008 .

[39]  S. Ommen,et al.  Evaluation of Left Ventricular Filling Pressures by Doppler Echocardiography in Patients With Hypertrophic Cardiomyopathy: Correlation With Direct Left Atrial Pressure Measurement at Cardiac Catheterization , 2007, Circulation.

[40]  M. Robson,et al.  Evidence for Microvascular Dysfunction in Hypertrophic Cardiomyopathy: New Insights From Multiparametric Magnetic Resonance Imaging , 2007, Circulation.

[41]  S. Nagueh,et al.  Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[42]  B. Maron,et al.  Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). , 2006, The American journal of cardiology.

[43]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[44]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[45]  M. Quiñones,et al.  Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.

[46]  D. Mozaffarian,et al.  Right ventricular involvement in hypertrophic cardiomyopathy , 2001 .

[47]  L. Faber,et al.  Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[48]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[49]  M. Condorelli,et al.  Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. , 1999, The American journal of cardiology.

[50]  B. Maron,et al.  Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.